Methodist Journal



The Burgeoning Field of Cardio-Oncology

See More

Barry H. Trachtenberg Leads Issue on Cardio-Oncology

See More


Heart Failure in Relation to Anthracyclines and Other Chemotherapies

Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies

The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics

Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity

Cardiovascular Toxicities of Radiation Therapy

Electrophysiologic Complications in Cancer Patients

Vascular Toxicity in Patients with Cancer: Is There a Recipe to Clarify Treatment?

Future Directions in Cardio-Oncology


A Rare Case of Pancreatitis-Induced Thrombosis of the Aorta and Superior Mesenteric Artery

Anomalous Origin of the Right Coronary Artery from the Left Main Coronary Artery in the Setting of Critical Bicuspid Aortic Valve Stenosis

Simultaneous Transfemoral Mitral and Tricuspid Valve in Ring Implantation: First Case Report with Edwards Sapien 3 Valve

Uneventful Follow-Up 2 Years after Endovascular Treatment of a High Flow Iatrogenic Aortocaval Fistula Causing Pulmonary Hypertension and Right Heart Failure


Do Not Pass Flow: Microvascular Obstruction on Cardiac Magnetic Resonance After Reinfarction Following Primary Percutaneous Coronary Intervention



Cardio-Oncology, Then and Now: An Interview with Barry Trachtenberg


Onconephrology: An Evolving Field


Herbal Nephropathy


Rolling the Dice on Red Yeast Rice


Letter to the Editor in Response to “Cardiac Autonomic Neuropathy in Diabetes Mellitus”

Vol 14, Issue 3 (2018)

Article Full Text


Venous Thrombosis in Nephrotic Syndrome

Jump to:
Article Citation:

Sharp W, Olivero JJ. Venous Thrombosis in Nephrotic Syndrome. Methodist DeBakey Cardiovasc J. 14(3):237-8.

nephrotic syndrome , NS , venous thrombosis , venous thromboembolism , VTE , arterial thromboembolism , ATE

The column in this issue is supplied by Whitney Sharp, D.O., and Juan Jose Olivero, M.D. Dr. Sharp is chief medical resident in internal medicine at Houston Methodist Hospital and earned her Doctor of Osteopathic Medicine degree at Nova Southeastern University in Fort Lauderdale, Florida. Dr. Olivero is a nephrologist at Houston Methodist Hospital and a member of the hospital’s Nephrology Training Program. He obtained his medical degree from the University of San Carlos School of Medicine in Guatemala, Central America, and completed his residency and nephrology fellowship at Baylor College of Medicine in Houston, Texas.

Nephrotic syndrome (NS) is the clinical constellation of proteinuria, edema, hypoalbuminemia, and hyperlipidemia. Understanding of pathophysiology and management of NS has improved in the last century with the advent of renal biopsy and the use of steroids, diuretics, and newer therapeutic interventions.¹ The etiology of NS can be primary or secondary. The most common primary etiologies according to different age groups include minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and amyloidosis. Systemic illnesses such as diabetes mellitus, lupus erythematosus, infectious diseases, and various malignancies constitute secondary etiologies. Known complications of NS include infection, intravascular volume depletion due to hypoalbuminemia leading to low colloid osmotic pressure and fluid extravasation (edema, bilateral pleural effusions, and ascites), anemia, acute kidney injury, malnutrition, and thromboembolism. Although the association of thromboembolism and NS has been recognized since 1948, the pathophysiology and management remain less clear.2


  1. The frequency of venous thromboembolism (VTE) and arterial thromboembolism (ATE) varies widely due to lack of prospective studies and underdiagnoses.
  2. ATE and VTE both occur in NS, although VTE is more common.2 VTE is most commonly found in the renal veins, but thrombi in the splenic vein, portal vein, cerebral venous sinuses, internal jugular vein, and vena cava have been reported, mainly in pediatric patients.3 ATE has also been reported in the aorta and mesenteric, axillary, femoral, ophthalmic, carotid, cerebral, renal, pulmonary, and coronary arteries, with the pulmonary and femoral arteries having the highest reported incidence.4
  3. The pathophysiology to explain the hypercoagulable state of NS remains elusive, but it is thought to be multifactorial with several implicated mechanisms. Nonselective massive proteinuria can result in loss of fibrinolytic proteins—such as antithrombin III, plasminogen, protein S, and plasmin—resulting in a procoaguable state.5
  4. Although anticoagulant substances are lost, an increase in prothrombotic substances by the liver can occur and further contribute to the hypercoagulable state. Fibrinogen, which enhances platelet activity and red blood cell aggregation, is increased in patients with NS. Additionally, patients with NS have higher levels of factor V, factor VII, and alpha-2 macroglobulin, which promote thrombus formation.5
  5. Hypoalbuminemia increases thromboxane A2 synthesis, which also promotes platelet adhesiveness. Additional mechanisms of platelet hyperactivity include hypercholesterolemia and increased Von Willebrand factor, which also promotes platelet adhesion. Furthermore, hypovolemia increases blood viscosity, contributing to increased red blood cell aggregation and clot formation.4,5
  6. Fibrinolysis is also compromised by urinary loss of plasmin (another essential fibrinolytic protein), which further contributes to the hypercoagulable state.5
  7. Presence of membranous nephropathy has the highest rates of VTE. Accurate histological diagnosis of VTE is important for identifying patients who are at highest risk for future thrombotic events.2 Additionally, patients with low serum albumin (< 2 gm/dL) have higher rates of VTE and ATE.2,4,5 Traditional risk factors for atherosclerotic emboli such as increased age, male sex, previous ATE, diabetes, hypertension, and history of smoking are associated with increased rates of ATE.2
  8. Treatment for ATE and VTE is based on individual patient characteristics, and the risk for bleeding should be considered with validated scoring systems before starting anticoagulation. Therapeutic anticoagulation for VTE and ATE, including asymptomatic renal vein thrombosis, should be considered for at least 6 to 12 months in the absence of contraindications; however, expert consensus is to treat patients until they are no longer nephrotic and normal albuminemia has been restored.5 Typical treatment regimens consist of unfractionated or low-molecular-weight heparin with transition to warfarin and some of the newer anticoagulants. There is limited evidence for the beneficial use of direct-acting oral anticoagulants. However, two case reports show successful use of these agents in renal vein thrombosis and carotid artery thrombosis complicating nephrotic syndrome.6,7 Inferior vena cava filters, catheter-directed thrombolysis, and thrombectomy are also therapeutic options under special circumstances, particularly when there are contraindications to systemic anticoagulation.
  9. Prophylactic anticoagulation has been proposed in patients with the highest risk of thrombosis with minimal bleeding risk—such as those with membranous nephropathy with low albumin—and without contraindications to anticoagulation.5
  1. Pal A, Kaskel F. History of nephrotic syndrome and evolution of its treatment. Front Pediatr. 2016 May 30;4:56.
  2. Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008 Jan 15;117(2):224-3.
  3. Al Azzawi HF, Obi OC, Safi J, Song M. Nephrotic syndrome-induced thromboembolism in adults. Int J Crit Illn Inj Sci. 2016 Apr-Jun;6(2):85-8.
  4. Fahal IH, McClelland P, Hay CR, Bell GM. Arterial thrombosis in the nephrotic syndrome. Postgrad Med J. 1994 Dec;70(830):905-9.
  5. Mirrakhimov AE, Ali AM, Barbaryan A, Prueksaritanond S, Hussain N. Primary Nephrotic Syndrome in Adults as a Risk Factor for Pulmonary Embolism: An Up-to-Date Review of the Literature. Int J Nephrol. 2014;2014:916760.
  6. Sasaki Y, Raita Y, Uehara G, Higa Y, Miyasato H. Carotid thromboembolism associated with nephrotic syndrome treated with dabigatran. Case Rep Nephrol Urol. 2014 Mar 21;4(1):42-52.
  7. Dupree LH, Reddy P. Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability. Ann Pharmacother. 2014;48(12):1655-8.

Add Comments

Please login to dialogue with author.